Chronic Liver Disease Therapeutics Market Driven by Macrophage-Based Innovations
The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
What Level Of Market Value Growth Is Predicted For The Chronic Liver Diseases Therapeutics Market From 2026 To 2030?
The chronic liver diseases therapeutics market has experienced significant growth in size over recent years. It is projected to increase from $15.88 billion in 2025 to $17.56 billion in 2026, at a compound annual growth rate (CAGR) of 10.6%. The expansion witnessed in previous periods is attributable to factors such as enhanced diagnosis of chronic liver conditions, the broader implementation of antiviral therapy, improved management of autoimmune liver diseases, more extensive access to hospital-based liver care, and the proliferation of specialty hepatology services.
The market for therapeutics related to chronic liver diseases is projected to undergo significant expansion in the coming years. It is foreseen to escalate to $25.99 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 10.3%. This anticipated growth during the forecast period is propelled by increasing investments in NASH and fibrosis therapies, a growing requirement for precision liver medicine, the broadening scope of biologic and targeted treatments, a heightened focus on early intervention strategies, and augmented clinical trial activities in liver diseases. Prominent trends throughout this period include the accelerated development of targeted liver therapies, an increasing emphasis on treatment approaches specific to individual diseases, the wider adoption of combination drug regimens, an expansion of non-invasive methods for disease monitoring, and a stronger focus on decelerating disease progression.
Access Your Free Sample Report For In-Depth Market Analysis:
Which Factors Are Influencing The Growth Of The Chronic Liver Diseases Therapeutics Market?
The chronic liver disease therapeutics market is anticipated to expand due to a rise in alcohol consumption. Alcohol consumption involves the intake of ethanol-containing drinks, which can vary from moderate to heavy usage, carrying possible health consequences. The worldwide increase in alcohol consumption can be attributed to heightened social acceptance, increased disposable incomes, and improved accessibility. Therapeutics for chronic liver disease assist in managing liver damage resulting from high alcohol intake, thereby decelerating disease advancement and enhancing liver function. For example, data from June 2024, provided by the First Citizens Bank, a US financial institution, showed a 1.2% rise in direct-to-consumer (DTC) wine case sales in 2023 compared to 2022. Furthermore, a report released in December 2023 by Kirin Holdings Company Limited, a Japan-based beverage company, indicated that approximately 192.1 million kiloliters of beer were consumed in 2022, marking a 2.9% increase from the prior year. Consequently, the rising levels of alcohol consumption are propelling the expansion of the chronic liver disease therapeutics market.
What Are The Different Segment Types In The Chronic Liver Diseases Therapeutics Market Segment Breakdown?
The chronic liver diseases therapeutics market covered in this report is segmented –
1) By Treatment Type: Antiviral Drugs, Immunosuppressants Vaccines, Immunoglobulins, Corticosteroids, Targeted Therapy, Chemotherapy
2) By Disease Type: Hepatitis, Autoimmune Diseases, Non-Alcoholic Fatty Liver Disease, Cancer, Genetic Disorders
3) By Application: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Antiviral Drugs: Nucleoside Or Nucleotide Analogues, Interferons, Direct-Acting Antivirals
2) By Immunosuppressants Vaccines: Calcineurin Inhibitors, mTOR Inhibitors, Purine Synthesis Inhibitors
3) By Immunoglobulins: Hepatitis B Immune Globulin, Intravenous Immunoglobulin
4) By Corticosteroids: Prednisolone, Methylprednisolone, Dexamethasone
5) By Targeted Therapy: Tyrosine Kinase Inhibitors, Monoclonal Antibodies
6) By Chemotherapy: Systemic Chemotherapy, Transarterial Chemoembolization Agents
Which Trends Are Influencing Demand In The Chronic Liver Diseases Therapeutics Market?
Leading companies in the chronic liver disease therapeutics market are concentrating on developing innovative solutions such as engineered autologous macrophage cell therapy to enhance liver regeneration, reduce fibrosis progression, and provide more targeted, disease-modifying treatment options. This particular treatment approach utilizes a patient’s own macrophages, which are genetically modified or functionally enhanced outside the body, and subsequently reinfused to lessen liver inflammation, foster tissue repair, and slow or reverse fibrosis in chronic liver diseases. For instance, in June 2024, Resolution Therapeutics Ltd., a UK-based biotechnology company, obtained approval from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) to begin its Phase I/II EMERALD study for the lead candidate RTX001, aimed at decompensated liver cirrhosis.
Who Are The Well-Known Companies In The Chronic Liver Diseases Therapeutics Market?
Major companies operating in the chronic liver diseases therapeutics market are F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Novo Nordisk A/S, Dr. Reddy’s Laboratories Ltd., Vir Biotechnology Inc., Alnylam Pharmaceuticals Inc., Indian Immunologicals Limited, Intercept Pharmaceuticals Inc., Viking Therapeutics Inc., Ascletis Pharma Inc., Ochre Bio Limited, Tiziana Life Sciences Ltd., Antios Therapeutics Inc.
Get The Full Chronic Liver Diseases Therapeutics Market Report:
Which Region Holds The Highest Market Share In The Chronic Liver Diseases Therapeutics Market?
North America was the largest region in the chronic liver diseases therapeutics market in 2025. The regions covered in the chronic liver diseases therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Chronic Liver Diseases Therapeutics Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Chronic Liver Diseases Therapeutics Market 2026, By The Business Research Company
Fatty Liver Treatment Market Report 2026
https://www.thebusinessresearchcompany.com/report/fatty-liver-treatment-global-market-report
Liver Health Supplements Market Report 2026
https://www.thebusinessresearchcompany.com/report/liver-health-supplements-global-market-report
Hepatitis Therapeutics Market Report 2026
https://www.thebusinessresearchcompany.com/report/hepatitis-therapeutics-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
